ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2392

Blood Vessel Instability and Oxidative Damage in Giant Cell Arteritis

Danielle Molloy1, Jennifer McCormick2, Mary Connolly2, Muhammad Haroon3, Douglas J. Veale2, Conor Murphy4, Ursula Fearon2 and Eamonn S. Molloy1, 1Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, 2Rheumatology, Dublin Academic Medical Center, St. Vincent's University Hospital, Dublin, Ireland, 3Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 4Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Angiogenesis, cytokines, giant cell arteritis and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Giant cell arteritis (GCA) is the most common form of primary vasculitis. The pathogenesis is incompletely understood, but involves neoangiogenesis and inflammatory infiltration of the arterial wall. The aim of the present study was to assess blood vessel stability and oxidative damage in patients with the condition and correlate with disease activity.

Methods:

20 patients with a clinical diagnosis of GCA were included, 16 of whom had a positive temporal artery biopsy. Temporal artery (TA) sections were assessed for blood vessel maturity (%BVM) by dual-immunofluorescent staining for Factor VIII/αSMA.  Oxidative DNA damage (8-oxo-7,8-dihydro-2’-deoxyguanosine; 8-oxo-dG), lipid peroxidation (4-hydroxy-2-nonenal; 4-HNE),  angiogenic growth factor Angiopoietin 2 (Ang2) and it receptor Tie-2 were assessed by immunohistochemistry. Ex vivo TA explant cultures were established directly from fresh biopsy specimens (n=4) and spontaneous release of pro-angiogenic factors were examined by ELISA and gelatine zymography. Patients were categorised into low disease (CRP<50) vs high disease activity (CRP>50).

Results:

Strong expression of 8-oxo-dG, 4HNE, Ang2 and Tie2 were demonstrated in the adventitial and intimal regions. 8-oxo-dG and 4HNE correlated with disease activity marker ESR (r=.568, p<0.017: r=.451, p<0.05 respectively). Expression of 8-oxodG significantly correlated with Tie2 (r=0.538, p<0.017) and that of 4HNE significantly correlated with Ang2 (r=0.0529, p<0.02).  A mixture of immature and mature blood vessels was demonstrated in all GCA patients, with a lower number of vessels expressing α-SMA in patients with high disease activity (41% ± 13.4) compared to low disease activity (66% ± 8.2) suggesting a more unstable vascular microenvironment is associated with high disease activity.  This was further supported when we demonstrated spontaneous release of pro-inflammatory mediators Ang2, MMP-2, MMP-9, IL-6 and IL-8 from ex vivo TA explants in culture. Furthermore conditioned media from TA explants significantly induced angiogenic tube formation (p<0.05). 

Conclusion:

This is the first study directly demonstrating that vessels in the inflamed temporal arteries from patients with GCA are unstable and are associated with incomplete EC/pericyte interactions, expression of Ang2 and oxidative damage markers.


Disclosure:

D. Molloy,
None;

J. McCormick,
None;

M. Connolly,
None;

M. Haroon,
None;

D. J. Veale,

Roche Pharmaceuticals,

5,

Pfizer Inc, MSD, Bayer,

5,

Pfizer Inc, MSD,

8;

C. Murphy,
None;

U. Fearon,
None;

E. S. Molloy,

Roche Pharmaceuticals,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/blood-vessel-instability-and-oxidative-damage-in-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology